Search our Database of Scientific Publications and Authors

I’m looking for a

    857 results match your criteria Buruli Ulcer

    1 OF 18

    Draft Genome Sequence of Mycobacterium ulcerans S4018 Isolated from a Patient with an Active Buruli Ulcer in Benin, Africa.
    Genome Announc 2017 Apr 27;5(17). Epub 2017 Apr 27.
    CRCINA, Inserm, CNRS, Université d'Angers, Université de Nantes, Nantes, France
    Currently, there are only two publicly available genomes of Mycobacterium ulcerans-the causative agent of the neglected, but devastating, tropical disease Buruli ulcer. Here, we report the draft genome sequence of isolate S4018, recovered from an active cutaneous lesion of a patient with Buruli ulcer in Benin, Africa. Read More

    Global and local environmental changes as drivers of Buruli ulcer emergence.
    Emerg Microbes Infect 2017 Apr 26;6(4):e22. Epub 2017 Apr 26.
    Institut de Recherche pour le Développement, Département Ecologie, Biodiversité et Fonctionnement des Ecosystemes Continentaux, UMR BOREA IRD 207, CNRS 7208, MNHN, UPMC, Muséum National d'Histoire Naturelle, 75231 Paris, France.
    Many emerging infectious diseases are caused by generalist pathogens that infect and transmit via multiple host species with multiple dissemination routes, thus confounding the understanding of pathogen transmission pathways from wildlife reservoirs to humans. The emergence of these pathogens in human populations has frequently been associated with global changes, such as socio-economic, climate or biodiversity modifications, by allowing generalist pathogens to invade and persist in new ecological niches, infect new host species, and thus change the nature of transmission pathways. Using the case of Buruli ulcer disease, we review how land-use changes, climatic patterns and biodiversity alterations contribute to disease emergence in many parts of the world. Read More

    Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients.
    Int J Med Microbiol 2017 Apr 19. Epub 2017 Apr 19.
    Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
    Buruli ulcer (BU) is a necrotizing infection of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. BU wounds may also be colonized with other microorganisms including Staphylococcus aureus. This study aimed to characterize the virulence factors of S. Read More

    Disease ecology, health and the environment: a framework to account for ecological and socio-economic drivers in the control of neglected tropical diseases.
    Philos Trans R Soc Lond B Biol Sci 2017 Jun;372(1722)
    Department of Biology, Hopkins Marine Station, Stanford University, Pacific Grove, CA 93950, USA.
    Reducing the burden of neglected tropical diseases (NTDs) is one of the key strategic targets advanced by the Sustainable Development Goals. Despite the unprecedented effort deployed for NTD elimination in the past decade, their control, mainly through drug administration, remains particularly challenging: persistent poverty and repeated exposure to pathogens embedded in the environment limit the efficacy of strategies focused exclusively on human treatment or medical care. Here, we present a simple modelling framework to illustrate the relative role of ecological and socio-economic drivers of environmentally transmitted parasites and pathogens. Read More

    Landscape and environmental influences on Mycobacterium ulcerans distribution among aquatic sites in Ghana.
    PLoS One 2017 24;12(4):e0176375. Epub 2017 Apr 24.
    Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
    Buruli ulcer, caused by Mycobacterium ulcerans, is highly endemic in West Africa. While the mode of transmission is unknown, many studies associate Buruli ulcer with different types of water exposure. We present results from the largest study to date to test for M. Read More

    Exposure Risk for Infection and Lack of Human-to-Human Transmission of Mycobacterium ulcerans Disease, Australia.
    Emerg Infect Dis 2017 May;23(5):837-840
    We conducted epidemiologic and genetic analyses of family clusters of Mycobacterium ulcerans (Buruli ulcer) disease in southeastern Australia. We found that the incidence of M. ulcerans disease in family members was increased. Read More

    Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer.
    PLoS Negl Trop Dis 2017 Apr 14;11(4):e0005553. Epub 2017 Apr 14.
    Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.
    Addressing the transmission enigma of the neglected disease Buruli ulcer (BU) is a World Health Organization priority. In Australia, we have observed an association between mosquitoes harboring the causative agent, Mycobacterium ulcerans, and BU. Here we tested a contaminated skin model of BU transmission by dipping the tails from healthy mice in cultures of the causative agent, Mycobacterium ulcerans. Read More

    In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials.
    Can J Infect Dis Med Microbiol 2017 14;2017:5180984. Epub 2017 Mar 14.
    Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
    Background. The current definitive treatment of Buruli ulcer with antibiotics makes the issue of antimicrobial drug resistance an unavoidable one. This is as a result of drug misuse by health personnel and patients' noncompliance to treatment regimen. Read More

    An Optimized Method for Extracting Bacterial RNA from Mouse Skin Tissue Colonized by Mycobacterium ulcerans.
    Front Microbiol 2017 24;8:512. Epub 2017 Mar 24.
    Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Université d'AngersAngers, France; Equipe Atip-Avenir, Center for Research in Cancerology and Immunology Nantes-Angers, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire et Université d'AngersAngers, France.
    Bacterial transcriptome analyses during host colonization are essential to decipher the complexity of the relationship between the bacterium and its host. RNA sequencing (RNA-seq) is a promising approach providing valuable information about bacterial adaptation, the host response and, in some cases, mutual tolerance underlying crosstalk, as recently observed in the context of Mycobacterium ulcerans infection. Buruli ulcer is caused by M. Read More

    Chronic cutaneous mycobacterial ulcers due to Mycobacterium ulcerans (Buruli ulcer): the first indigenous case report from Jordan and a literature review.
    Int J Infect Dis 2017 Mar 23;58:77-81. Epub 2017 Mar 23.
    Internal Medicine Department, Jordan Hospital and Medical Center, Amman, Jordan.
    Background: Buruli ulcer is the third most common mycobacterial infection worldwide. It is endemic in tropical, subtropical, and temperate climates. It causes devastating disease with morbidity and mortality. Read More

    [Nontuberculous mycobacteria].
    Hautarzt 2017 Mar 22. Epub 2017 Mar 22.
    Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
    Dermatologically relevant nontuberculous mycobacteria (NTM) include Mycobacterium marinum and Mycobacterium ulcerans and different rapidly growing mycobacteria (RGM). RGM are widely present in the environment and are facultative pathogenic. Diagnostic detection of nontuberculous mycobacteria is frequently challenging. Read More

    Experimental demonstration of the possible role of Acanthamoeba polyphaga in the infection and disease progression in Buruli Ulcer (BU) using ICR mice.
    PLoS One 2017 22;12(3):e0172843. Epub 2017 Mar 22.
    Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana.
    The transmission of Buruli ulcer (BU), caused by Mycobacterium ulcerans (MU), remains puzzling although a number of hypothesis including through bites of infected aquatic insects have been proposed. We report the results of experiments using ICR mice that give credence to our hypothesis that Acanthamoeba species may play a role in BU transmission. We cocultured MU N2 and MU 1615 which expresses red fluorescent protein (RFP) and Acanthamoeba polyphaga (AP), and confirmed infected AP by Ziehl-Neelsen (ZN) staining. Read More

    Ecology and Feeding Habits Drive Infection of Water Bugs with Mycobacterium ulcerans.
    Ecohealth 2017 Mar 17. Epub 2017 Mar 17.
    UMR MIVEGEC IRD, CNRS, Université de Montpellier, Centre IRD de Montpellier, BP 64501, 34394, Montpellier Cedex, France.
    Mycobacterium ulcerans (MU), the causative agent of Buruli ulcer, is present in a wide spectrum of environments, including terrestrial and aquatic ecosystems in tropical regions. The most promising studies on the epidemiological risk of this disease suggest that some ecological settings may favor infection of animals with MU including human. A species' needs and impacts on resources and the environment, i. Read More

    The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.
    ACS Chem Biol 2017 Mar 27. Epub 2017 Mar 27.
    Swiss Tropical and Public Health Institute , Socinstrasse 57, 4002 Basel, Switzerland.
    Mycolactone, the macrolide exotoxin produced by Mycobacterium ulcerans, is central to the pathogenesis of the chronic necrotizing skin disease Buruli ulcer (BU). Here we show that mycolactone acts as an inhibitor of the mechanistic Target of Rapamycin (mTOR) signaling pathway by interfering with the assembly of the two distinct mTOR protein complexes mTORC1 and mTORC2, which regulate different cellular processes. Inhibition of the assembly of the rictor containing mTORC2 complex by mycolactone prevents phosphorylation of the serine/threonine protein kinase Akt. Read More

    Genomic analysis of ST88 community-acquired methicillin resistant Staphylococcus aureus in Ghana.
    PeerJ 2017 28;5:e3047. Epub 2017 Feb 28.
    Department of Microbiology and Immunology, Doherty Applied Microbial Genomics, Doherty Institute for Infection and Immunity, University of Melbourne , Melbourne, VIC , Australia.
    Background: The emergence and evolution of community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) strains in Africa is poorly understood. However, one particular MRSA lineage called ST88, appears to be rapidly establishing itself as an "African" CA-MRSA clone. In this study, we employed whole genome sequencing to provide more information on the genetic background of ST88 CA-MRSA isolates from Ghana and to describe in detail ST88 CA-MRSA isolates in comparison with other MRSA lineages worldwide. Read More

    Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana.
    PLoS Negl Trop Dis 2017 Feb 28;11(2):e0005331. Epub 2017 Feb 28.
    Section Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.
    Background: Beyond Mycobacterium ulcerans-specific therapy, sound general wound management is required for successful management of Buruli ulcer (BU) patients which places them among the large and diverse group of patients in poor countries with a broken skin barrier.

    Methods: Clinically BU suspicious patients were enrolled between October 2013 and August 2015 at a primary health care (PHC) center and a municipal hospital, secondary health care (SHC) center in Ghana. All patients were IS2404 PCR tested and divided into IS2404 PCR positive and negative groups. Read More

    Cutaneous basidiobolomycosis: Seven cases in southern Benin.
    Ann Dermatol Venereol 2017 Apr 24;144(4):250-254. Epub 2017 Feb 24.
    Dermatology department, CNHU-HKM, faculté des sciences de la santé, BP 186, Cotonou, Benin.
    Background: Cutaneous basidiobolomycosis is the most common form of entomophthoramycosis. Herein we report seven cases of cutaneous basidiobolomycosis.

    Patients And Methods: A retrospective observational study was conducted at the Buruli ulcer treatment centre in Pobè and at the national teaching hospital in Cotonou from 2010 to 2015. Read More

    Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.
    PLoS Negl Trop Dis 2017 Feb 27;11(2):e0005415. Epub 2017 Feb 27.
    Kumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi, Ghana.
    Background: Buruli ulcer disease (BUD), caused by Mycobacterium (M.) ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. BUD causes necrotic skin lesions and is a significant problem for health care in the affected countries. Read More

    Seasonal Pattern of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer, in the Environment in Ghana.
    Microb Ecol 2017 Feb 25. Epub 2017 Feb 25.
    Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana.
    This study aimed to contribute to the understanding of Mycobacterium ulcerans (MU) ecology by analysing both clinical and environmental samples collected from ten communities along two major river basins (Offin and Densu) associated with Buruli ulcer (BU) at different seasons. We collected clinical samples from presumptive BU cases and environmental samples from ten communities. Following DNA extraction, clinical samples were confirmed by IS2404 PCR and environmental samples were confirmed by targeting MU-specific genes, IS2404, IS2606 and the ketoreductase (KR) using real-time PCR. Read More

    Mycobacterium ulcerans mycolactone interferes with adhesion, migration and proliferation of primary human keratinocytes and HaCaT cell line.
    Arch Dermatol Res 2017 Apr 22;309(3):179-189. Epub 2017 Feb 22.
    Department of Translational Medicine, University of Piemonte Orientale "A. Avogadro", Via Solaroli 17, 28100, Novara, Italy.
    The pathogenicity of Mycobacterium ulcerans (Buruli ulcer) is closely associated with the secretion of exotoxin mycolactone. The cytotoxicity of mycolactone has been linked to its apoptogenic activity. We explored if low mycolactone concentrations, which are not able to induce apoptosis, can influence other essential activities on two primary human keratinocyte populations, keratinocyte stem cells (KSC) and transit amplifying cells (TAC), and on a human keratinocyte line, HaCaT. Read More

    Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis.
    J Cell Sci 2017 Apr 20;130(7):1307-1320. Epub 2017 Feb 20.
    Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Michael Smith Building, Manchester M13 9PT, UK
    Mycolactone is the exotoxin virulence factor produced by Mycobacterium ulcerans, the pathogen responsible for Buruli ulcer. The skin lesions and immunosuppression that are characteristic of this disease result from the action of mycolactone, which targets the Sec61 complex and inhibits the co-translational translocation of secretory proteins into the endoplasmic reticulum. In this study, we investigate the effect of mycolactone on the Sec61-dependent biogenesis of different classes of transmembrane protein (TMP). Read More

    Molecular Characterization of Mycolactone Producing Mycobacteria from Aquatic Environments in Buruli Ulcer Non-Endemic Areas in Côte d'Ivoire.
    Int J Environ Res Public Health 2017 Feb 11;14(2). Epub 2017 Feb 11.
    Department of Environment and Health, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), Adiopodoumé, 01 BP 1303, Abidjan 01, Côte d'Ivoire.
    Non-tuberculous mycobacteria (NTM), particularly mycolactone producing mycobacteria (MPM), are bacteria found in aquatic environments causing skin diseases in humans like Buruli ulcer (BU). Although the causative agent for BU, Mycobacterium ulcerans has been identified and associated with slow-moving water bodies, the real transmission route is still unknown. This study aimed to characterize MPMs from environmental aquatic samples collected in a BU non-endemic community, Adiopodoumé, in Côte d'Ivoire. Read More

    Design, synthesis, and cytotoxicity of stabilized mycolactone analogs.
    Bioorg Med Chem Lett 2017 Mar 17;27(5):1274-1277. Epub 2017 Jan 17.
    Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA. Electronic address:
    On exposure to visible light, mycolactone A/B, the causative toxin of Buruli ulcer, rearranges to a mixture of four photo-mycolactones apparently via a rare photochemically-induced [4πs+2πa] cycloaddition. In order to prevent the rearrangement, two C6'-C7' dihydromycolactone analogs 6'α-15 and 6'β-15 were designed and synthesized. 6'α-15 and 6'β-15 were shown to be stable under not only photochemical, but also acidic and basic conditions. Read More

    Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
    Pan Afr Med J 2016 1;25(Suppl 1):13. Epub 2016 Oct 1.
    Ghana Field Epidemiology and Laboratory Training programme, School of Public Health, University of Ghana.
    Introduction: Buruli ulcer (BU) is an infectious skin disease, caused by Mycobacterium ulcerans, endemic in more than 30 countries worldwide especially Africa. Brong-Ahafo Region implemented WHO recommended daily treatment with streptomycin and rifampicin for eight weeks (SR8). Yet limited assessment of therapy exists. Read More

    Multiple Introductions and Recent Spread of the Emerging Human Pathogen Mycobacterium ulcerans across Africa.
    Genome Biol Evol 2017 Mar;9(3):414-426
    Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
    Buruli ulcer (BU) is an insidious neglected tropical disease. Cases are reported around the world but the rural regions of West and Central Africa are most affected. How BU is transmitted and spreads has remained a mystery, even though the causative agent, Mycobacterium ulcerans, has been known for more than 70 years. Read More

    Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection.
    Int J Antimicrob Agents 2017 Mar 9;49(3):290-295. Epub 2017 Jan 9.
    Aix-Marseille Université, INSERM, CNRS, IRD, URMITE, Marseille, France. Electronic address:
    Mycobacterium ulcerans is responsible for Buruli ulcer, characterised by extensive, disabling ulcers. Standard treatment combining rifampicin and streptomycin exposes patients to toxicity and daily painful injections. In this study, the in vitro susceptibilities of 3 M. Read More


    High-Throughput Carbon Substrate Profiling of Mycobacterium ulcerans Suggests Potential Environmental Reservoirs.
    PLoS Negl Trop Dis 2017 Jan 17;11(1):e0005303. Epub 2017 Jan 17.
    Aix Marseille Univ, INSERM, CNRS, IRD, URMITE, Marseille, France.
    Background: Mycobacterium ulcerans is a close derivative of Mycobacterium marinum and the agent of Buruli ulcer in some tropical countries. Epidemiological and environmental studies pointed towards stagnant water ecosystems as potential sources of M. ulcerans, yet the ultimate reservoirs remain elusive. Read More

    Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    JBI Database System Rev Implement Rep 2017 Jan;15(1):119-139
    1The Cameroon Centre for Evidence Based Health Care: a Joanna Briggs Institute Centre of Excellence, Yaounde, Cameroon, Africa 2Centre for Behavioral and Social Research, Yaounde, Cameroon, Africa 3Centre for Evidence Based Initiatives in Health Care: a Joanna Briggs Institute Centre of Excellence, University of Wollongong, Wollongong, New South Wales, Australia 4St George Hospital, Sydney, New South Wales, Australia.
    Background: Buruli ulcer (BU) disease is a chronic ulcerative skin disease caused by Mycobacterium ulcerans, which can lead to extensive destruction of the skin, soft tissues and occasionally of bones. Although several antibiotics have demonstrated bactericidal activity against M. ulcerans in vitro, no consensus on their clinical efficacy against M. Read More

    Phytotherapy against buruli ulcer in the Health District of Yamoussoukro (Cote d'Ivoire) : Identification, description, and symbolic functions of the plants and recipes used.
    Med Sante Trop 2016 Nov;26(4):408-413
    Centre suisse de recherches sentifiques en Côte d'Ivoire, 01 BP 1303 Abidjan 01, Côte d'Ivoire.
    This study aims to describe the plants and recipes proposed by traditional healers against Buruli ulcer in Côte d'Ivoire and to analyze their symbolic aspects. Buruli ulcer is an increasingly serious health problem in Côte d'Ivoire. The ivorian state through the National Buruli Ulcer Control Programme and its partners, has developed various actions to fight that disease. Read More

    Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana.
    Int J Microbiol 2016 14;2016:8304524. Epub 2016 Dec 14.
    Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
    Background. Drug resistance is a major challenge in antibiotic chemotherapy. Assessing resistance profiles of pathogens constitutes an essential surveillance tool in the epidemiology and control of infectious diseases, including Buruli ulcer (BU) disease. Read More

    Epidemiology of Mansonella perstans in the middle belt of Ghana.
    Parasit Vectors 2017 Jan 7;10(1):15. Epub 2017 Jan 7.
    Department of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
    Background: Mansonellosis was first reported in Ghana by Awadzi in the 1990s. Co-infections of Mansonella perstans have also been reported in a small cohort of patients with Buruli ulcer and their contacts. However, no study has assessed the exact prevalence of the disease in a larger study population. Read More

    Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs.
    BMC Microbiol 2017 Jan 5;17(1). Epub 2017 Jan 5.
    Swiss Tropical Institute, Basel, Switzerland.
    Background: Mycobacterium ulcerans (M. ulcerans) is the causative agent of Buruli Ulcer (BU) disease. In order to inhibit the growth of the microbial contaminants during culture of M. Read More

    Antimycobacterial potency and cytotoxicity study of three medicinal plants.
    Int J Mycobacteriol 2016 Dec 27;5 Suppl 1:S206-S207. Epub 2016 Oct 27.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana.
    Objective/background: Mycobacterial infections including tuberculosis, leprosy, and buruli ulcer are among the most prevalent, debilitating, and deadly tropical diseases, especially in Sub-Saharan Africa. The development of drug resistance to the currently available drugs and the poor compliance emphasize the need for new chemotherapeutic agents. This study was designed to evaluate the in vitro activity of Cleistopholis patens, Annona reticulata, and Greenwayodendron suaveolens against Mycobacterium smegmatis. Read More

    Antimycobacterial ingredients from plants used in traditional medicine to treat Buruli ulcer.
    Int J Mycobacteriol 2016 Dec 29;5 Suppl 1:S204-S205. Epub 2016 Nov 29.
    Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, Accra, Ghana; Department of Pharmacology and Toxicology, School of Pharmacy, University of Ghana, Accra, Ghana.
    Aim And Objectives: Buruli ulcer (BU) is a neglected tropical disease caused by a mycobacteria, Mycobacterium ulcerans. The WHO recommended Rifampicin-Streptomycin combination side effects and poor compliance, leaves rural populations with no choice than to patronise indigenous remedies. This study is aimed at validating medicinal plants used in traditional medicine to treat BU by investigating the in vitro efficacy and safety as well as their composition in active molecules. Read More

    Antimycobacterial activity of medicinal plants against the causative agent of buruli ulcer: Mycobacterium ulcerans.
    Int J Mycobacteriol 2016 Dec 23;5 Suppl 1:S105. Epub 2016 Nov 23.
    Antimicrobial and Biocontrol Agents Unit, Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
    Objective/background: Buruli ulcer, known as necrotizing skin disease caused by Mycobacterium ulcerans, has emerged as the most prevalent mycobacteriosis after leprosy and tuberculosis. Accordingly, it has been classified by the World Health Organization as a neglected disease with high significance in tropical areas, including Cameroon. So far, the control of the disease relies mainly on the rifampin-streptomycin combination. Read More

    Characteristics and epidemiological profile of Buruli ulcer in the district of Tiassalé, south Côte d'Ivoire.
    Acta Trop 2016 Dec 27. Epub 2016 Dec 27.
    Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët-Boigny, 01 BP V 34, Abidjan 01, Côte d'Ivoire.
    Buruli ulcer (BU) is a cutaneous infectious disease caused by Mycobacterium ulcerans. It is the third most common mycobacterial disease in the world in the immunocompetent patient and second in Côte d'Ivoire after tuberculosis. This study aimed to assess the characteristics and epidemiological profile of BU in the district of Tiassalé, an important focus of the disease in south Côte d'Ivoire, in order to better direct actions for prevention and control. Read More

    Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
    PLoS Negl Trop Dis 2016 Dec 29;10(12):e0005261. Epub 2016 Dec 29.
    University of Groningen, University Medical Center Groningen, Department of Internal Medicine/Infectious Diseases, Groningen, The Netherlands.
    Background: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical disease frequently leading to permanent disabilities. The ulcers are treated with rifampicin and streptomycin, wound care and, if necessary surgical intervention. Professionals have exclusively shaped the research agenda concerning management and control, while patients' perspective on priorities and preferences have not explicitly been explored or addressed. Read More

    Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria.
    Rev Soc Bras Med Trop 2016 Nov-Dec;49(6):746-751
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria.
    Introduction:: Mycolactones, secreted by Mycobacterium ulcerans, were previously believed to prevent super infection in Buruli ulcer lesions. However, little is known about secondary bacterial infections in these lesions. This study evaluated contaminating bacterial flora and their antibiotic susceptibility patterns in cases of previously untreated Buruli ulcer disease from three states in Southern Nigeria. Read More

    Financial burden of health care for Buruli ulcer patients in Nigeria: the patients' perspective.
    Int Health 2017 Jan 15;9(1):36-43. Epub 2016 Dec 15.
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria
    Background: The economic burden of Buruli ulcer for patients has not been well-documented. This study assessed the costs of Buruli ulcer care to patients from the onset of illness to diagnosis and to the end of treatment.

    Methods: This was a cross-sectional cost of illness study conducted among patients with Buruli ulcer in four States in Nigeria between July and September 2015. Read More

    Deforestation-driven food-web collapse linked to emerging tropical infectious disease, Mycobacterium ulcerans.
    Sci Adv 2016 Dec 7;2(12):e1600387. Epub 2016 Dec 7.
    Faculty of Science and Technology, Department of Life and Environmental Sciences, Bournemouth University, Dorset BH12 5BB, UK.; Institut de Recherche pour le Développement, UMR MIVEGEC IRD-CNRS-Université de Montpellier, Centre IRD de Montpellier, BP 64501, Montpellier, France.; Institut de Recherche pour le Développement, UMR BOREA IRD-MNHN-Université Pierre et Marie Curie, Muséum National d'Histoire Naturelle, 47 rue Cuvier, 75231 Paris cedex 5, France.
    Generalist microorganisms are the agents of many emerging infectious diseases (EIDs), but their natural life cycles are difficult to predict due to the multiplicity of potential hosts and environmental reservoirs. Among 250 known human EIDs, many have been traced to tropical rain forests and specifically freshwater aquatic systems, which act as an interface between microbe-rich sediments or substrates and terrestrial habitats. Along with the rapid urbanization of developing countries, population encroachment, deforestation, and land-use modifications are expected to increase the risk of EID outbreaks. Read More

    Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
    PLoS Negl Trop Dis 2016 Dec 12;10(12):e0005229. Epub 2016 Dec 12.
    Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
    Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells, recombinant MU DNA, or MU protein prime-boosts, have shown promise by conferring transient protection to mice against the pathology of MU challenge. Recently, we have shown that a recombinant BCG vaccine expressing MU-Ag85A (BCG MU-Ag85A) displayed the highest level of protection to date, by significantly extending the survival time of MU challenged mice compared to BCG vaccination alone. Read More

    Mycobacterium ulcerans toxin, mycolactone may enhance host-seeking and oviposition behaviour by Aedes aegypti (L.) (Diptera: Culicidae).
    Environ Microbiol 2017 May 25;19(5):1750-1760. Epub 2017 Jan 25.
    Texas A&M University, College Station, TX, USA.
    The ecological functions of many toxins continue to remain unknown for those produced by environmental pathogens. Mycobacterium ulcerans, the causative agent of the neglected tropical disease, Buruli ulcer, produces a cytotoxic macrolide, mycolactone, whose function(s) in the environment remains elusive. Through a series of dual-choice behaviour assays, they show that mycolactone may be an interkingdom cue for the yellow fever mosquito, Aedes aegypti, seeking blood-meals as well as oviposition sites. Read More

    Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.
    PLoS One 2016 28;11(11):e0167059. Epub 2016 Nov 28.
    Swiss Tropical and Public Health Institute, Basel, Switzerland.
    Buruli Ulcer is a neglected tropical disease leading to extensive disabilities and morbidity in West Africa. In this paper we sought to characterize various strains of Mycobacterium ulcerans (M.ulcerans) with different origins and laboratory passage records while refining a mouse model for Buruli ulcer. Read More

    Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients.
    Am J Trop Med Hyg 2016 Nov 12;95(5):1011-1015. Epub 2016 Sep 12.
    Department of Internal Medicine/Infectious Diseases Groningen, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
    Buruli ulcer (BU) is one of the 17 neglected tropical diseases for which the World Health Organization has adopted resolutions to improve treatment. BU was previously described as a relatively painless condition; however, recent research has indicated that some patients experience substantial pain. The objective of this study was to explore patients' experiences of pain and their expectations for its treatment. Read More

    Mycobacterium ulcerans in the Daintree 2009-2015 and the mini-epidemic of 2011.
    ANZ J Surg 2016 Nov 1. Epub 2016 Nov 1.
    Department of Surgery, Cairns Hospital, Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia.
    Background: Mycobacterium ulcerans infection (Buruli ulcer) is the third most common mycobacterial disease in humans, with presentations ranging from self-limiting skin nodules and ulcers to aggressive infiltrative infections with extensive oedema, fat and skin necrosis. The two foci in Australia are in Victoria and Far North Queensland. We present the 2009-2015 case series for the Queensland focus with special reference to the 2011 spike of 64 cases. Read More

    Diagnosis delay and duration of hospitalisation of patients with Buruli ulcer in Nigeria.
    Trans R Soc Trop Med Hyg 2016 Sep 23;110(9):502-509. Epub 2016 Oct 23.
    Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria
    Background: Delayed diagnosis of Buruli ulcer can worsen clinical presentation of the disease, prolong duration of management, and impose avoidable additional costs on patients and health providers. We investigated the profile, delays in diagnosis, duration of hospitalisation, and associated factors among patients with Buruli ulcer in Nigeria.

    Methods: This was a prospective cohort study of patients with Buruli ulcer who were identified from a community-based survey. Read More

    RNA Aptamer That Specifically Binds to Mycolactone and Serves as a Diagnostic Tool for Diagnosis of Buruli Ulcer.
    PLoS Negl Trop Dis 2016 Oct 24;10(10):e0004950. Epub 2016 Oct 24.
    Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
    Background: Buruli ulcer (BU) is a subcutaneous skin disease listed among the neglected tropical diseases by the World Health Organization (WHO). Early case detection and management is very important to reduce morbidity and the accompanied characteristic disfiguring nature of BU. Since diagnosis based on clinical evidence can lead to misdiagnosis, microbiological confirmation is essential to reduce abuse of drugs; since the anti-mycobacterial drugs are also used for TB treatment. Read More

    Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    PLoS Negl Trop Dis 2016 Oct 18;10(10):e0005066. Epub 2016 Oct 18.
    Sorbonne Universités, UPMC Univ Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), F-75013, Paris, France.
    Background: The treatment of Buruli ulcer (BU) that is caused by Mycobacterium ulcerans, is currently based on a daily administration of rifampin and streptomycin (RIF-STR). A fully oral intermittent regimen would greatly simplify its treatment on the field.

    Methodology/principal Findings: The objective of this study was to assess the bactericidal and sterilizing activities of intermittent oral regimens in a murine model of established M. Read More

    The Burden of Leprosy in Cameroon: Fifteen Years into the Post-elimination Era.
    PLoS Negl Trop Dis 2016 Oct 12;10(10):e0005012. Epub 2016 Oct 12.
    Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon.
    Background: Cameroon achieved the elimination target of leprosy in 2000, and has maintained this status ever since. However, a number of health districts in the country continue to report significant numbers of leprosy cases. The aim of this study was to assess the burden of leprosy in Cameroon from 2000 to 2014. Read More

    1 OF 18